Displaying drugs 11501 - 11525 of 11930 in total
Motavizumab
Investigational
Dirlotapide
Dirlotapide is a drug employed in the treatment of obesity in dogs. It is marketed by Pfizer and Zoetis under the brand name, Slentrol, and is not intended for human use.
Investigational
Vet approved
Matched Description: … Dirlotapide is a drug employed in the treatment of obesity in dogs. …
S-777469
S-777469 is under investigation in clinical trial NCT00703573 (A Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis).
Investigational
Matched Description: … S-777469 is under investigation in clinical trial NCT00703573 (A Randomized, Double-blind Study to Evaluate …
SBT101
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
Matched Description: … SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector …
Fencamfamin
Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the...
Experimental
Illicit
Withdrawn
Matched Description: … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite ... It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers …
XL784
XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied...
Investigational
Matched Description: … XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because …
Fucoxanthin
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green ... A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing. …
Pozanicline
ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity Disorder and Schizophrenia/Schizoaffective disorders. In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR...
Investigational
Matched Description: … ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for …
Zalutumumab
Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
Investigational
Matched Description: … Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal …
PZM21
PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine.
Experimental
Matched Description: … PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment …
EGT-101
EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.
Investigational
Matched Description: … Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A. …
Dimethylthiambutene
Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug. It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available.
Experimental
Illicit
Dihydroxyacetone phosphate
Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Investigational
Etrinabdione
Investigational
Glyceryl 1-oleate
Experimental
Tilmicosin
Tilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia haemolytica.
Investigational
Vet approved
Matched Description: … Tilmicosin is a macrolide antibiotic. …
Theanine
Theanine, a precursor of ethylamine, is found in green tea. It is under investigation in clinical trial NCT00291070 (Effects of L-Theanine in Boys With ADHD).
Investigational
Matched Description: … Theanine, a precursor of ethylamine, is found in green tea. …
Iboctadekin
Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).
Investigational
Matched Description: … Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to …
PF-04634817
PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
Investigational
Matched Description: … PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine …
Ponezumab
Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Investigational
Matched Description: … Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 …
Vorsetuzumab mafodotin
Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
Investigational
Matched Description: … Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN- …
Pegbelfermin
Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
Investigational
Matched Description: … Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication …
HSK-3486
HSK-3486 is under investigation in clinical trial NCT04620031 (A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation).
Investigational
Matched Description: … HSK-3486 is under investigation in clinical trial NCT04620031 (A Study Evaluating Sedation of Intravenous …
Neihulizumab
Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.
Investigational
Matched Description: … Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby …
Erfonrilimab
Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
Investigational
Matched Description: … Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand …
Displaying drugs 11501 - 11525 of 11930 in total